Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Non-Current Assets: 2009-2025

Historic Non-Current Assets for Lifecore Biomedical (LFCR) over the last 16 years, with May 2025 value amounting to $153.7 million.

  • Lifecore Biomedical's Non-Current Assets fell 11.14% to $153.7 million in Q2 2025 from the same period last year, while for May 2025 it was $153.7 million, marking a year-over-year decrease of 11.14%. This contributed to the annual value of $153.7 million for FY2025, which is 11.14% down from last year.
  • According to the latest figures from Q2 2025, Lifecore Biomedical's Non-Current Assets is $153.7 million, which was up 0.12% from $153.5 million recorded in Q1 2025.
  • Lifecore Biomedical's Non-Current Assets' 5-year high stood at $356.6 million during Q2 2021, with a 5-year trough of $153.5 million in Q1 2025.
  • Its 3-year average for Non-Current Assets is $164.1 million, with a median of $166.0 million in 2023.
  • Its Non-Current Assets has fluctuated over the past 5 years, first skyrocketed by 161.44% in 2021, then tumbled by 55.68% in 2022.
  • Quarterly analysis of 5 years shows Lifecore Biomedical's Non-Current Assets stood at $270.8 million in 2021, then slumped by 42.05% to $156.9 million in 2022, then climbed by 7.78% to $169.1 million in 2023, then increased by 2.62% to $173.5 million in 2024, then fell by 11.14% to $153.7 million in 2025.
  • Its last three reported values are $153.7 million in Q2 2025, $153.5 million for Q1 2025, and $173.5 million during Q4 2024.